Every Form 4 that TScan Therapeutics, Inc. (TCRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow TCRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TCRX filings page.
On October 1, 2026, TScan Therapeutics, Inc. CEO Gavin MacBeath received an award of 1,000,000 shares of Voting Common Stock in the form of restricted stock units (RSUs). His reported direct holdings after the award were 1,049,767 shares. Twenty-five percent of the RSUs vest on September 30, 2028; the remaining 75% vest on the earlier of reporting of completion of the TSC-101 pivotal trial or September 30, 2030, subject to continued service and the terms of the equity incentive plan and award agreement.
TScan Therapeutics, Inc. (TCRX) Chief Legal and Strategy Officer Zoran Zdraveski received an award reported as 300,000 shares of Voting Common Stock on October 1, 2026. His reported direct holdings following the transaction were 304,716 shares.
The award terms provide that 25% of the RSUs vest on September 30, 2028; the remaining 75% vest on the earlier of reported completion of the pivotal TSC-101 trial or September 30, 2030, subject to continued service through the applicable vesting dates and the plan and award agreement terms.
BAKER BROS. ADVISORS LP reported acquisition or exercise transactions in this Form 4 filing.
TScan Therapeutics, Inc. reported an insider Form 4 showing an award of 67,000 non-qualified stock options linked to its common stock. The options were granted to Dr. Stephen R. Biggar, who serves on the board, with a strike price of $0.9946 per share and expiration on May 19, 2036.
The options vest on the earlier of the first anniversary of the May 20, 2026 grant date or the next annual stockholder meeting, subject to Dr. Biggar’s continued board service. Under Baker Bros. Advisors LP policies, Dr. Biggar does not retain economic rights in these securities; related Baker funds instead hold an indirect proportionate pecuniary interest, and Baker-affiliated entities disclaim beneficial ownership beyond that interest.
TScan Therapeutics director Keith Woods received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. All 67,000 underlying shares vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, subject to his continued service. Following this grant, he holds options for 67,000 shares directly.
TScan Therapeutics director Garry A. Nicholson received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036. They vest in full on the earlier of May 20, 2027 or the next annual stockholder meeting, subject to his continued service.
TScan Therapeutics director Gabriela Gruia received a grant of stock options as part of her compensation. The award covers 67,000 options to buy Voting Common Stock at an exercise price of $0.9946 per share and expires on May 20, 2036.
According to the terms, these options will vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, provided she continues in service through that date. This filing reflects an equity grant, not an open‑market purchase or sale of shares.
TScan Therapeutics director Katina Dorton received a grant of stock options covering 67,000 shares of Voting Common Stock. The options have an exercise price of $0.9946 per share and expire on May 20, 2036.
The options vest and become exercisable in full on the earlier of May 20, 2027 or the next annual meeting of stockholders, as long as she continues in service. After this grant, she holds 67,000 options directly, and there were no reported share purchases or sales in this filing.
TScan Therapeutics director Barbara Klencke received a new stock option grant covering 67,000 shares of Voting Common Stock. The option has an exercise price of $0.9946 per share and expires on May 20, 2036. The entire grant will vest and become exercisable upon the earlier of May 20, 2027 or the company’s next annual stockholder meeting, provided she continues serving the company through that date. Following this grant, she holds options on 67,000 shares directly.
TScan Therapeutics granted Chief Financial Officer Jason Amello a stock option for 350,000 shares of voting common stock on January 20, 2026. The option has an exercise price of $1.12 per share and was awarded at no cost to the executive. Following this grant, Amello beneficially owns options for 350,000 shares.
The award vests over time: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on his continued service with the company.
TScan Therapeutics, Inc. granted stock options to its Chief Executive Officer and director, Gavin MacBeath. On January 20, 2026, he received a stock option to purchase 1,165,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted at no cost for the derivative itself.
According to the vesting terms, 25% of the shares subject to the option will vest and become exercisable on the one-year anniversary of January 20, 2026, with the remaining shares vesting in equal monthly installments over the following 36 months. Vesting is conditioned on his continued service to the company on each vesting date. Following this grant, MacBeath beneficially owned 1,165,000 derivative securities directly.
TScan Therapeutics, Inc. reported that officer Dworak Leiden received a stock option grant covering 100,000 shares of voting common stock on January 20, 2026. The option has an exercise price of $1.12 per share and was awarded at no cost for the derivative itself. The grant vests 25% of the shares on the one-year anniversary of January 20, 2026, with the remaining shares vesting in equal monthly installments over the next 36 months, conditioned on continued service. Following this award, the reporting person beneficially owns 100,000 derivative securities directly.
TScan Therapeutics granted its Chief Medical Officer, Louis Chrystal, a stock option covering 420,000 shares of voting common stock at an exercise price of $1.12 per share. The option was granted on January 20, 2026 and is held directly. The award vests over four years: 25% of the shares vest on the one-year anniversary of January 20, 2026, with the remaining 75% vesting in equal monthly installments over the following 36 months, conditioned on Chrystal’s continued service with the company on each vesting date.
TScan Therapeutics reported that officer Zoran Zdraveski, Chief Legal and Strategy Officer, received a grant of 350,000 stock options on January 20, 2026. These options give the right to buy TScan voting common stock at an exercise price of $1.12 per share and expire on January 20, 2036.
According to the vesting terms, 25% of the options vest on the one-year anniversary of January 20, 2026, with the remaining options vesting in equal monthly installments over the following 36 months, subject to Mr. Zdraveski’s continued service with the company. After this grant, he beneficially owns 350,000 derivative securities directly in the form of these options.